| Literature DB >> 32388650 |
Zoltán Ruszkai1, Erika Kiss2, Ildikó László2, Gergely Péter Bokrétás3, Dóra Vizserálek3, Ildikó Vámossy3, Erika Surány3, István Buzogány4, Zoltán Bajory5, Zsolt Molnár6.
Abstract
Applying lung protective mechanical ventilation (LPV) during general anaesthesia even in patients with non-injured lungs is recommended. However, the effects of an individual PEEP-optimisation on respiratory mechanics, oxygenation and their potential correlation with the inflammatory response and postoperative complications have not been evaluated have not been compared to standard LPV in patients undergoing major abdominal surgery. Thirty-nine patients undergoing open radical cystectomy were enrolled in this study. In the study group (SG) optimal PEEP was determined by a decremental titration procedure and defined as the PEEP value resulting the highest static pulmonary compliance. In the control group (CG) PEEP was set to 6 cmH2O. Primary endpoints were intraoperative respiratory mechanics and gas exchange parameters. Secondary outcomes were perioperative procalcitonin kinetics and postoperative pulmonary complications. Optimal PEEP levels (median = 10, range: 8-14 cmH2O), PaO2/FiO2 (451.24 ± 121.78 mmHg vs. 404.15 ± 115.87 mmHg, P = 0.005) and static pulmonary compliance (52.54 ± 13.59 ml cmH2O-1 vs. 45.22 ± 9.13 ml cmH2O-1, P < 0.0001) were significantly higher, while driving pressure (8.26 ± 1.74 cmH2O vs. 9.73 ± 4.02 cmH2O, P < 0.0001) was significantly lower in the SG as compared to the CG. No significant intergroup differences were found in procalcitonin kinetics (P = 0.076). Composite outcome results indicated a non-significant reduction of postoperative complications in the SG. Intraoperative PEEP-optimization resulted in significant improvement in gas exchange and pulmonary mechanics as compared to standard LPV. Whether these have any effect on short and long term outcomes require further investigations. Trial registration: Clinicaltrials.gov, identifier: NCT02931409.Entities:
Keywords: Inflammatory response; Lung protective ventilation; Positive end-expiratory pressure; Procalcitonin; Respiratory mechanics
Mesh:
Year: 2020 PMID: 32388650 PMCID: PMC7222900 DOI: 10.1007/s10877-020-00519-6
Source DB: PubMed Journal: J Clin Monit Comput ISSN: 1387-1307 Impact factor: 2.502
Protocolized perioperative care and procedures
| Preoperative period |
|---|
| Central venous catheter insertion followed by a chest X-ray in order to evaluate catheter position and exclude any insertion-related complications |
| Blood sampling to measure participant’s baseline PCT levels |
| Deep vein thrombosis prophylaxis (enoxaparine) |
| Antimicrobial prophylaxis (ciprofloxacin and metronidazole) |
| Oral carbohydrate loading (maltodextrin) |
| Intraoperative period |
| General anaesthesia combined with lumbar epidural analgesia |
| Lung protective ventilation applying FiO2 of 50% in both groups |
| Continuous invasive arterial blood pressure monitoring |
| Continuous capnography and heart rate monitoring |
| Respiratory mechanics parameters (static pulmonary compliance, airway resistance, dead space fraction) data recording every 15 min |
| Core temperature and train-of-four relaxometry data recording every 15 min |
| Regular ABG and CVBG sampling every 60 min |
| Maintenance fluid: 3 ml kg−1 h−1 of balanced crystalloid solution until the end of surgery |
| Rescue fluid: 200 ml of colloid solution bolus (hydroxyethyl starch) and crystalloid substitution in case of bleeding |
| Transfusion: PRBC transfusion, whenever the attending anaesthetist rendered it necessary |
| Vasopressor treatment: intravenous norepinephrine to maintain MAP above 65 mmHg |
| PCT sampling: 2 and 6 h after surgical incision intraoperatively |
| Postoperative period (POD1-3) |
| Continuous epidural analgesia combined with intravenous analgesics |
| Continuous intraabdominal pressure monitoring |
| Intravenous and oral fluid supplementation and if required, further transfusion |
| Oral clear fluids immediately after surgery |
| Removal of nasogastric tube at the latest on POD1 in the morning |
| Prokinetics and an oral liquid diet from POD1 |
| Active mobilization with the help of a physiotherapist from POD1 |
| Evaluation of patient’s ABG, CVBG, PaO2/FiO2 and dCO2 every 6 h from POD1 to POD3 |
| Evaluation of PCT levels at 12, 24, 48 and 72 h after surgical incision |
| Chest X-ray (evaluated by an independent trained radiologist who was not be involved in the study) on POD1, POD2 and POD3 |
| Monitoring of patients' clinical progress and secondary endpoints by daily SOFA scores, laboratory and physical examinations |
| Follow-up period (POD4-28) |
| Evaluation of secondary endpoints, in-hospital stay, 28-days and in-hospital mortality |
PCT procalcitonin; FiO fractional inspired oxygen; ABG arterial blood gas sample; CVBG central venous blood gas sample; PRBC packed red blood cells; MAP mean arterial pressure; POD postoperative day; PaO/FiO ratio of arterial oxygen partial pressure to fractional inspired oxygen; dCO central venous-to-arterial carbon dioxide difference; PPC postoperative pulmonary complications; SOFA sequential organ failure assessment
Secondary endpoints
| Endpoint | Time frame | Detailed description |
|---|---|---|
| Hypoxaemia | 3 days | PaO2/FiO2 < 300 mmHg |
| Circulatory failure | 28 days | Hypotension—MAP < 65 mmHg Severe cardiac arrhythmia—40/min < HR > 150/min ScvO2 < 70% dCO2 > 7 mmHg Serum lactate > 2 mmol/L Severe metabolic acidosis (actual bicarbonate < 18 mmol/L) Acute coronary syndrome Acute left ventricular failure Pulmonary embolism Cardiac arrest |
| Gastrointestinal dysfunction | 28 days | Constipation Ileus Anastomotic leakage Reoperation Disorders of liver function |
| Renal dysfunction | 28 days | RIFLE criteria |
| Hematologic and coagulation disorders | 28 days | Severe bleeding Coagulopathy—INR > 1.5 |
| Infection | 28 days | Any infection except from pneumonia |
PaO/FiO ratio of arterial oxygen partial pressure to fraction of inspired oxygen; MAP mean arterial pressure; HR heart rate; ScvO central venous oxygen saturation; dCO arterial to central venous carbon dioxide difference; INR international normalized ratio
Fig. 1CONSORT (Consolidated Standards of Reporting Trials) flow diagram showing the progress of participants during the trial
Demographic data and clinical characteristics
| CG (n = 15) | SG (n = 15) | ||
|---|---|---|---|
| Male sex (n) | 1.000 | ||
| Age (years) | 61.47 (7.37) | 64.27 (7.03) | 0.245 |
| ASA physical status | |||
| 1 | |||
| 2 | |||
| 3 | |||
| RFRI (%) | 2.57 [2.05–3.57] | 2.78 [2.09–3.78] | 0.479 |
| ARISCAT score | 45.67 [42.47–50.46] | 44.4 [41.88–47.51] | 0.644 |
| BMI (kg m−2) | 27.42 (4.00) | 27.66 (2.58) | 0.829 |
| IBW (kg) | 67.33 (8.79) | 67.44 (9.52) | 0.971 |
| Duration of anaesthesia (min) | 384.00 (107.01) | 418.2 (70.49) | 0.342 |
| Duration of surgery (min) | 352.47 (103.58) | 378.00 (63.52) | 0.442 |
| Type of surgery | |||
| Ileal conduit | 0.208 | ||
| Orthotopic bladder substitute | 0.105 | ||
| Intraoperative inoperablea | 0.551 | ||
| PEEP during surgery (cmH2O) | |||
| 6 | |||
| 8 | |||
| 10 | |||
| 12 | |||
| 14 |
Data are expressed as number n (%), mean (SD) or median [IQR]
ASA American Society of Anesthesiologists physical status classification; RFRI Respiratory Failure Risk Index (Gupta); ARISCAT Score Assess Respiratory Risk in Surgical Patients in Catalonia; BMI body mass index, IBW ideal body weight (calculation was based on the ARMA Trial of the ARDS Network Investigators); PEEP positive end-expiratory pressure; SD standard deviation; IQR interquartile range
aDue to intraoperatively observed intraabdominal status or excessive propagation of bladder tumor, only radical cystectomy and ureterocutaneostomy was performed without ileal conduit
Italics value indicates number of subjects or number of events
Intraoperative respiratory mechanics and oxygenation
| CG (n = 15) | SG (n = 15) | ||
|---|---|---|---|
| PaO2/FiO2 (mmHg) | 404.15 (115.87) | 451.24 (121.78) | 0.005 |
| Cstat (ml cmH2O−1) | 45.22 (9.13) | 52.54 (13.59) | < 0.0001 |
| Vds/Vt (%) | 23.05 [20.05–25.50] | 21.14 [17.94–24.93] | 0.001 |
| Raw (cmH2O L−1 s−1) | 6.84 (2.39) | 5.86 (1.31) | < 0.0001 |
| P (cmH2O) | 9.73 (4.02) | 8.26 (1.74) | < 0.0001 |
| Respiratory rate (min−1) | 16.04 [14.04–16.75] | 17.07 [15.01–18.87] | 0.0001 |
| EtCO2 (mmHg) | 37.63 [36.23–38.16] | 38.00 [36.96–39.52] | 0.017 |
| (a-Et)PCO2 (mmHg) | 7.25 (0.92) | 5.76 (1.39) | 0.007 |
Data are expressed as mean (SD) or median [IQR]
Cstat static pulmonary compliance; Vds/Vt dead space fraction; Raw airway resistance; △P driving pressure; EtCO end-tidal carbon dioxide tension; (a-Et)PCO arterial to end-tidal carbon dioxide difference; PaO/FiO ratio of arterial oxygen partial pressure to fraction of inspired oxygen; SD standard deviation; IQR interquartile range
Intraoperative haemodynamic parameters and management
| CG (n = 15) | SG (n = 15) | ||
|---|---|---|---|
| MAP (mmHg) | 79 [72–84] | 76 [71–83.25] | 0.040 |
| HR (min−1) | 74 [67–82] | 72 [61–85] | 0.062 |
| ScvO2 (%) | 86.8 [82.95–89.98] | 85.9 [81.90–89.30] | 0.248 |
| dCO2 (mmHg) | 6.3 [4.75–7.98] | 6.65 [4.90–8.05] | 0.724 |
| Lactate (mmol l−1) | 1.1 [0.83–1.50] | 1.2 [0.98–1.40] | 0.277 |
| pH | 7.33 (0.04) | 7.32 (0.04) | 0.307 |
| stHCO3− (mmol l−1) | 22.70 (1.42) | 21.83 (1.52) | 0.0002 |
| Fluid management | |||
| Crystalloids (ml) | 2212.53 (1102.16) | 2331.53 (889.49) | 0.775 |
| Colloids (ml) | 433.33 (225.72) | 573.33 (194.45) | 0.078 |
| Fluids (ml kg−1 h−1) | 3.99 [3.08–4.63] | 4.41 [3.37–5.06] | 0.646 |
| ∑ Fluids (ml) | 3765.87 (1218.72) | 3931.53 (1006.09) | 0.745 |
| Urine output (ml) | 1051.33 (423.39) | 1023.33 (606.47) | 0.741 |
| Blood loss (ml) | 1000.0 (622.5) | 1250.0 (882.5) | 0.125 |
| Fluid balance (ml) | 1702.4 (1054.42) | 1566.73 (1071.56) | 0.761 |
| PRBC units transfused (U) | 2 [0–2] | 2 [0–2] | 0.859 |
| 0 U | 1.000 | ||
| 1–3 U | 0.705 | ||
| > 3 U | 0.626 | ||
| Norepinephrine (mcg min−1) | 3 [0–5] | 7 [ | < 0.0001 |
| ∑ Norepinephrine (mg) | 1.29 [0.40–2.85] | 2.8 [1.99–5.01] | 0.006 |
Data are expressed as number n (%), mean (SD) or median [IQR]
MAP mean arterial pressure; HR heart rate; ScvO central venous oxygen saturation; dCO arterial to central venous carbon dioxide difference; stHCO arterial standard bicarbonate; PRBC packed red blood cells; U unit; SD standard deviation; IQR interquartile range
Italics value indicates number of subjects or number of events
Postoperative results on POD1 to POD3
| POD1 | POD2 | POD3 | Composite results | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| CG (n = 15) | SG (n = 15) | CG (n = 15) | SG (n = 15) | CG (n = 15) | SG (n = 15) | CG (n = 15) | SG (n = 15) | OR (95% CI) | ||
| Oxygenation | ||||||||||
| PaO2/FiO2 (mmHg) | 277.75 (72.79) | 299.85 (79.61) | 279.77 (81.43) | 270.02 (70.63) | 310.31 (87.98) | 311.83 (70.10) | 298.67 (44.68) | 307.60 (48.22) | 0.63 (0.25–1.63) | 0.342 |
| Haemodynamic data | ||||||||||
| MAP (mmHg) | 80.27 (14.06) | 79.97 (15.14) | 88.50 (13.84) | 83.07 (16.79) | 89.67 (10.57) | 84.13 (14.45) | 75.20 (10.97) | 72.39 (11.74) | 1.19 (0.52–2.73) | 0.673 |
| HR (min−1) | 84.13 (15.83) | 82.07 (18.91) | 80.00 (21.0) | 83.50 (20.0) | 80.67 (10.39) | 81.97 (14.24) | 82.23 (9.21) | 82.82 (11.57) | 1.12 (0.44–2.90) | 0.809 |
| ScvO2 (%) | 71.54 (7.56) | 70.67 (7.72) | 70.45 (5.89) | 70,78 (5.73) | 71.31 (6.11) | 70.49 (6.89) | 71.64 (4.47) | 70.94 (5.15) | 0.89 (0.36–2.25) | 0.814 |
| dCO2 (mmHg) | 6.58 (2.92) | 7.04 (2.58) | 6.68 (2.75) | 6.02 (2.41) | 6.25 (2.06) | 5.73 (1.96) | 5.96 (2.59) | 5.76 (2.38) | 0.43 (0.17–1.08) | 0.072 |
| Lactate (mmol l−1) | 1.28 (0.45) | 1.58 (0.74) | 1.09 (0.38) | 1.25 (0.65) | 1.22 (0.48) | 1.02 (0.33) | 1.20 (0.44) | 1.28 (0.63) | 3.72 (1.09–12.64) | 0.057 |
| pH | 7.43 (0.04) | 7.42 (0.05) | 7.43 (0.03) | 7.44 (0.05) | 7.42 (0.02) | 7.43 (0.03) | 7.43 (0.03) | 7.43 (0.04) | 0.33 (0.01–8.22) | 0.496 |
| stHCO3− (mmol l−1) | 25.19 (2.17) | 24.48 (2.77) | 25.14 (2.56) | 25.84 (2.72) | 24.71 (2.45) | 25.07 (1.88) | 25.02 (2.38) | 25.13 (2.53) | 1.05 (0.47–2.95) | 0.705 |
| IAP (mmHg) | 12.99 (6.19) | 11.69 (5.63) | 13.86 (7.93) | 12.08 (5.12) | 12.16 (6.68) | 11.75 (3.97) | 13.03 (6.92) | 11.84 (4.92) | 0.45 (0.23–0.87) | 0.062 |
| Fluid management | ||||||||||
| Crystalloids (ml) | 3000 [2500–3587] | 3000 [2700–3000] | 2700 [2000–3262] | 2500 [1650–3325] | 2500 [1500–2975] | 1600 [1500–2075] | 2800 [2000–3187] | 2300 [1600–3000] | 0.314 | |
| Colloids (ml) | 200 [0–200] | 400 [300–450] | 0 [0–0] | 0 [0–100] | 0 [0–0] | 0 [0–0] | 0 [0–0] | 0 [0–25] | 0.083 | |
| Oral intake (ml) | 1200 [1100–1925] | 800 [525–1100] | 1300 [1050–2000] | 1400 [875–1738] | 2000 [1325–2425] | 1500 [1225–2000] | 1400 [1100–2000] | 1230 [750–1850] | 0.089 | |
| Urine output (ml) | 3050 [2125–4150] | 2460 [2125–2900] | 3800 [2745–4538] | 2800 [2713–3425] | 3700 [3050–4185] | 2600 [2150–3175] | 3600 [2835–4300] | 2750 [2275–3212] | 0.001 | |
| Blood loss (ml) | 50 [0–200] | 100 [0–200] | 0 [0–0] | 0 [0–0] | 0 [0–0] | 0[0–0] | 0 [0–0] | 0 [0–12.5] | 0.685 | |
| Fluid balance (ml) | 800 [490–2185] | 1700 [660–1890] | 200 [-640 to 1580] | 830 [-62 to 2125] | 300 [-12 to 950] | 800 [-25 to 1575] | 460 [-100 to 1532] | 1200 [162–1938] | 0.114 | |
| PRBC units transfused | ||||||||||
| 0 U | 1.55 (0.62–3.88) | 0.354 | ||||||||
| 1–3 U | 0.57 (0.22–1.46) | 0.242 | ||||||||
| > 3 U | 0.33 (0.01–8.22) | 0.496 | ||||||||
| Laboratory results | ||||||||||
| Platelet count (G l−1) | 197 (57.57) | 191 (40.92) | 183 (56.47) | 163 (38.47) | 186 (63.93) | 162 (45.99) | 189 (58.41) | 172 (42.97) | 1.12 (0.52–3.25) | 0.814 |
| Bilirubin (μmol l−1) | 10.4 (3.09) | 16.6 (13.08) | 7.9 (2.36) | 12.3 (9.90) | 8.5 (2.33) | 10.7 (6.54) | 8.9 (2.77) | 13.2 (10.28) | 5.50 (0.62–19.11) | 0.127 |
| Creatinine (μmol l−1) | 102 [83.50–132.75] | 131 [94.00–180.75] | 94 [80.00–123.75] | 136 [88.50–163.00] | 92.0 [79.25–128.50] | 124.0 [73.25–157.25] | 94 [80.00–128.25] | 131 [88.75–166.50] | 2.05 (0.89–4.75) | 0.022 |
| BUN (mmol l−1) | 4.9 [3.9–5.9] | 5.1 [4.3–8.8] | 4.4 [3.4–5.4] | 5.3 [3.5–7.6] | 4.8 [3.9–5.5] | 5.1 [4.5–7.9] | 4.6 [3.8–5.3] | 5.1 [4.3–7.9] | 3.25 (0.61–6.52) | 0.044 |
Data are expressed as number n (%), mean (SD) or median [IQR]
POD postoperative day; CG control group; SG study group; OR odds ratio; PaO/FiO ratio of arterial oxygen partial pressure to fractional inspired oxygen; MAP mean arterial pressure; HR heart rate; ScvO central venous oxygen saturation; dCO arterial to central venous carbon dioxide difference; stHCO arterial standard bicarbonate; IAP intraabdominal pressure; PRBC packed red blood cells; U unit; BUN blood urea nitrogen; SD standard deviation; IQR interquartile range
Italics value indicates number of subjects or number of events
Fig. 2Median procalcitonin values indicating procalcitonin kinetics of groups. PCT procalcitonin; PCT baseline; PCT 2 h after surgical incision; PCT 6 h; PCT 12 h; PCT 24 h; PCT 48 h; PCT 72 h
Outcome results
| CG (n = 15) | SG (n = 15) | OR (95% CI) | ||
|---|---|---|---|---|
| Secondary outcome | ||||
| PaO2/FiO2 (mmHg) | 298.67 (44.68) | 307.60 (48.22) | 0.63 (0.25–1.63) | 0.342 |
| Circulatory | 1.15 (0.91–1.48) | 0.249 | ||
| Gastrointestinal | 0.73 (0.56–0.97) | 0.026 | ||
| Renal | 1.31 (0.83–2.16) | 0.270 | ||
| Haematologic | 0.89 (0.45–1.68) | 0.745 | ||
| Infection | 3.03 (1.26–7.28) | 0.013 | ||
| Tertiary outcome | ||||
| ICU length of stay (days) | 4 [ | 3 [ | 0.33 (0.08–1.48) | 0.108 |
| In-hospital stay (days) | 20.20 (13.08) | 18.23 (11.45) | 0.94 (0.21–4.29) | 0.678 |
| Mortality | 3.21 (0.12–85.20) | 0.486 | ||
| Composite outcome | 0.94 (0.81–1.09) | 0.396 |
Data are expressed as number n (%), mean (SD) or median [IQR]
CG control group; SG study group; OR odds ratio; PaO/FiO ratio of arterial oxygen partial pressure to fraction of inspired oxygen; ICU intensive care unit
Italics value indicates number of subjects or number of events
Fig. 3Composite outcome for postoperative complications. Composite outcome results indicated a slight, but not significant decrease in postoperative complications in SG as compared to CG. POD postoperative day; CG control group; SG study group